Gilead Sciences EBIT

As of the most recent data (June 2026), GILD shows a EBIT of $-1.7B. That compares with $8.2B in the prior-year period — down 120.4% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GILD's EBIT is now $-1.7B (was $8.2B) — a 120.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Gilead Sciences is outperforming or lagging.

The Healthcare sector average EBIT is about $110B. Gilead Sciences is at $-1.7B, which is lower that average. That is roughly 101.6% below the sector mean. Use the comparison chart on this page to see how GILD stacks up against individual peers as well.

Tracking GILD's ebit over time shows whether Gilead Sciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-1.7B That compares with $8.2B in the prior-year period — down 120.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Gilead Sciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-1.7B) with ownership activity and broader fundamentals.